Cardio-renal-metabolic syndrome (CRMS) is increasingly gaining clinical attention as the prevalence of the contributing disorders continues to rise. The definition of this syndrome remains not yet well established. It is hypothesized that CRMS results from a complex interplay among obesity, chronic kidney disease (CKD), diabetes, and cardiovascular diseases (CVDs), including coronary artery disease, heart failure, atrial fibrillation, stroke, and peripheral artery disease. Moreover, the metabolic dysfunction–associated kidney disease (MDAKD) is a term that describes kidney disease arising from metabolic dysfunction, often in the context of metabolic syndrome, and is characterized by the presence of CKD in individuals with metabolic abnormalities such as obesity, insulin resistance, diabetes mellitus, dyslipidemia, and hypertension.

The lack of prevention and inadequate control of the diseases contributing to CRMS are associated with increased mortality and morbidity due to CVDs, the risk of multi-organ failure, and substantial costs arising from hospitalizations. Recently, notable progress has been made in the treatment of heart failure, obesity, and CKD. The introduction of novel pharmacological agents, such as sodium-glucose cotransporter 2 (SGLT-2 inhibitors), glucagon-like peptide-1 (GLP1) agonists, non-steroidal mineralocorticoid receptor (MR) antagonist, and aldosterone synthase inhibitors has improved prognosis and symptom management within the CRMS population.

This special issue aims to compile these advancements and offer innovative insights into CRMS. Authors are encouraged to submit both original research articles and comprehensive reviews that illuminate the various facets of CRMS and MDAKD.
Potential areas of interest may include, but are not limited to:
● Obesity related disease in general population.
● Pathophysiology, clinical issue of CRMS/MDAKD
● Diagnostic of CRMS and MDAKD.
● Treatment management of patients with obesity, heart disease and CKD - the holistic point of view.
● Effects on public health and specific health conditions in CRMS/MDAKD population.

Authors are welcome to submit articles presenting original studies or literature review work. Please consult the journal's information regarding Article Types, Author Guidelines, and Publishing Fees, or direct any questions to the Editorial Office: abp@frontierspartnerships.org.

Even though abstract submission is not mandatory, we encourage all interested researchers to submit a “manuscript summary” before submitting their article. Manuscript summaries do not have to coincide with the final abstract of the article.

Authors

Acta Biochimica Polonica